Rhythm Pharmaceuticals Price Target Cut to $114.00/Share From $130.00 by Needham

What happened

Needham kept its Buy rating on Rhythm Pharmaceuticals but lowered its price target to $114.00 per share from $130.00, according to ratings actions reported by Benzinga.

Confirmed

Global impact / market context

A lower price target means Needham still expects the stock to rise, just less than before. Investors often read that as slightly reduced optimism about future profit, which can weigh on buying decisions.

Analyst inference

Analyst rating changes give investors a simple signal about expected share performance. Keeping Buy while cutting the target suggests confidence in the company remains but expectations for gains have been trimmed.

Analyst inference

What to watch

1. Needham maintained its Buy rating on Rhythm Pharmaceuticals while cutting the price target to $114.00 from $130.00. Confirmed
2. Watch whether other analysts follow with their own target changes, which could shift how investors view the stock. Proposed
3. Watch the share price reaction, since a lower target can reduce investor demand even when the Buy rating stays. Analyst inference

Evidence

• Original source link unavailable